Advertisement Pharmaceutical Business review - Page 369 of 5222 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
October 1, 2024

FDA grants approval for Fresenius-Formycon’s biosimilar Otulfi

The US Food and Drug Administration (FDA) has granted approval for Fresenius Kabi and Formycon’s Otulfi (ustekinumab-aauz), a ustekinumab biosimilar to the reference medicine Stelara (ustekinumab).

Otulfi is intended to treat Crohn’s disease, moderate to severe plaque psoriasis, ulcerative colitis and active psoriatic arthritis. Credit: Eszter Miller from Pixabay.